Cixutumumab
Stage IV Breast Cancer AJCC v6 and v7
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Stage IV Breast Cancer AJCC v6 and v7 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FES F-18 University of Washington | Phase 3 | BB |
Ruxolitinib Phosphate Mayo Clinic | Phase 1 | CC |
DARATUMUMAB Mayo Clinic | Phase 1 | CC |
Obinutuzumab Mayo Clinic | Phase 1 | CC |
Carfilzomib Mayo Clinic | Phase 1 | CC |
ror1 car-specific autologous t-lymphocytes Fred Hutchinson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Cixutumumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →